<DOC>
	<DOCNO>NCT02905396</DOCNO>
	<brief_summary>Small fibre neuropathy ( SFN ) disorder selectively thinly myelinated unmyelinated nerve fibre involve . SFN cause severe chronic symptom burn pain extremity combination autonomic symptom . So far , result symptomatic SFN treatment rather disappointing , despite fact new agent develop . This study pilot study investigate whether Spinal Cord Stimulation ( SCS ) combine best ( drug ) treatment usual ( TAU ) lead clinically significant pain relief patient suffer pain low limb due SFN , define ≥30 % pain reduction mean NRS daytime , and/or ≥30 % pain reduction mean NRS night-time , and/or least much improve much improve , Patient Global Impression Change ( PGIC ) pain sleep .</brief_summary>
	<brief_title>Spinal Cord Stimulation Small Fibre Neuropathy</brief_title>
	<detailed_description>Small fibre neuropathy ( SFN ) cause dysfunction Aδ-fibres C-fibres . SFN diagnose typical SFN symptom together abnormal intraepidermal nerve fibre density ( IENFD ) skin biopsy and/or abnormal temperature threshold quantitative sensory testing ( QST ) . A large number disorder underlie SFN , diabetes , amyloidosis , sarcoidosis systemic illness , vasculitis , HIV . The proportion idiopathic cryptogenic SFN report literature varies 24 % 93 % . SFN rare condition ; recent study show minimum prevalence 53/100.000 . SFN cause severe chronic symptom burn pain particularly extremity combination autonomic symptom , significant impact quality life . Moreover , neuropathic pain disorder associate anxiety , depression sleep disturbance , polypharmacy significant healthcare resource use . Therefore , neuropathic pain significant impact society due high socioeconomic cost . The treatment SFN still largely rely agent generally use neuropathic pain relief , particularly derive diabetic painful neuropathic study , antidepressant ( amitriptyline , duloxetine ) , anti-epileptic agent ( pregabalin , gabapentin ) , opioids topical agent ( lidocain capsaicin ) , disappoint SFN ( clinical observation &gt; 400 patient treat ) . Therefore major importance develop new treatment option provide sufficient pain relief individual patient . In 1965 Melzack Wall introduce gate theory pain perception . This theory offer new perspective treat neuropathic pain . In seventy SCS introduce . It think stimulation large myelinated fibre modulate transmission pain signal , run small , non-myelinated fibre . The exact mechanism SCS still unknown . Nowadays SCS use worldwide global sale estimate 35.000 system annually . Recently , prospective two-centre randomize control trial performed investigate effect SCS painful diabetic polyneuropathy . SCS successful 59 % patient , effect last least 2.5 year patient . The current pilot study focus potential effect SCS patient SFN . The main study parameter mean pain intensity measure Numeric Rating Scale ( NRS ) and/or Patient Global Impression Change ( PGIC ) pain sleep measure 7-point Likert scale , 12 month treatment patient SFN intractable neuropathic pain low limb . Besides primary objective , follow secondary aim investigate : 1 . The effect SCS pain ( least 30 % pain reduction , mean daily , night , maximum pain ) ; 2. effect SCS activity participation ; 3. effect SCS health relate quality life ; 4. effect SCS mood SFN ; 5. effect SCS reduction pain medication .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Erythromelalgia</mesh_term>
	<criteria>SFN diagnosis accord international criterion , Age 18 75 year , lucid , Mean pain intensity daytime nighttime 5 high 11points numeric rating scale ( NRS ) , The pain intend treat present 12 month , declare patient best knowledge study available medical record , Previous treatment unsuccessful ( insufficient pain relief and/or unacceptable sideeffects ) drug follow drug category Tricyclic antidepressant agent ( e.g. , Amitriptyline ) Alpha 2delta calcium channel agonist/Antiepileptic drug ( e.g . Pregabalin ( Lyrica ) Gabapentin ( Neurontin ) ) , Serotoninnorepinephrine reuptake inhibitor ( e.g. , Duloxetine ( Cymbalta ) ) , Tramadol strong opioids . Patients treat treated least 3 drug mention drug category accord EFNS guideline neuropathic pain [ 34 ] . Starting dosage base individual patient characteristic . Each drug try least 3 week dose raise , possible . Drug treatment stop due insufficient pain relief and/or unacceptable adverse event . Patients steady state medication use least 2 month prior inclusion . Neuromodulation history , Neuropathic pain prevalent upper limb ( UL ) compare leg ; UL NRS exceed 3 ) Neuropathy chronic pain origin SFN ( NRS &gt; 3 ) , Addiction : drug , alcohol ( 5E / day ) and/or specific medication Drugs : cocaine , heroin , marihuana , Alcohol : wine , beer , liquor , Medication : benzodiazepine . Insufficient cooperation patient ( little motivation , understand communication problem ) , Blood clot disorder use oral anticoagulation stop period 10 day around implantation procedure . Immune deficiency ( HIVpositive know , corticosteroid dose equivalent &gt; prednisolone 10 mg , immunosuppressive medication , etc . ) Known peripheral vascular disease , palpable peripheral pulsation foot ( inclusion possible pulsation absent , ankle/brachial index 0.7 1.2 foot ) Life expectancy &lt; 1 year Pacemaker Local infection skin disorder site incision Other clinically significant unstable , severe acute chronic medical psychiatric/psychological condition laboratory abnormality may increase risk associate study participation procedure may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Pregnancy Severe cardiac pulmonary failure ( &gt; NYHA classification II ) Use opioids ( high dose equivalent 30 mg morphine day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>small fiber neuropathy</keyword>
	<keyword>spinal cord stimulation</keyword>
	<keyword>treatment</keyword>
	<keyword>pain</keyword>
</DOC>